{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["33"],"submitter":["Lang P"],"funding":["Sanofi"],"pubmed_abstract":["Previous data have suggested an antiviral effect of teriflunomide, including against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the agent underlying the ongoing COVID-19 pandemic. We undertook an <i>in vitro</i> investigation to evaluate the inhibitory activity of teriflunomide against SARS-CoV-2 in a cell-based assay. Teriflunomide was added to Vero (kidney epithelial) cells that had been infected with SARS-CoV-2. A nucleocapsid immunofluorescence assay was performed to examine viral inhibition with teriflunomide and any potential cytotoxic effect. The 50% effective concentration (EC<sub>50</sub>) for teriflunomide against SARS-CoV-2 was 15.22 μM. No cytotoxicity was evident for teriflunomide in the Vero cells (i.e., the 50% cytotoxic concentration [CC<sub>50</sub>] was greater than the highest test concentration of 100 μM). The data were supported by additional experiments using other coronaviruses and human cell lines. In the SARS-CoV-2-infected Vero cells, the prodrug leflunomide had an EC<sub>50</sub> of 16.49 μM and a CC<sub>50</sub> of 54.80 μM. Our finding of teriflunomide-mediated inhibition of SARS-CoV-2 infection at double-digit micromolar potency adds to a growing body of evidence for a broad-ranging antiviral effect of teriflunomide."],"journal":["Biochemistry and biophysics reports"],"pagination":["101395"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9682045"],"repository":["biostudies-literature"],"pubmed_title":["<i>In vitro</i> evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43."],"pmcid":["PMC9682045"],"pubmed_authors":["Lublin AL","Geertsen SS","Lang P","Gladysheva T","Potter MC","Gregory JS","Rufi P"],"additional_accession":[]},"is_claimable":false,"name":"<i>In vitro</i> evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43.","description":"Previous data have suggested an antiviral effect of teriflunomide, including against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the agent underlying the ongoing COVID-19 pandemic. We undertook an <i>in vitro</i> investigation to evaluate the inhibitory activity of teriflunomide against SARS-CoV-2 in a cell-based assay. Teriflunomide was added to Vero (kidney epithelial) cells that had been infected with SARS-CoV-2. A nucleocapsid immunofluorescence assay was performed to examine viral inhibition with teriflunomide and any potential cytotoxic effect. The 50% effective concentration (EC<sub>50</sub>) for teriflunomide against SARS-CoV-2 was 15.22 μM. No cytotoxicity was evident for teriflunomide in the Vero cells (i.e., the 50% cytotoxic concentration [CC<sub>50</sub>] was greater than the highest test concentration of 100 μM). The data were supported by additional experiments using other coronaviruses and human cell lines. In the SARS-CoV-2-infected Vero cells, the prodrug leflunomide had an EC<sub>50</sub> of 16.49 μM and a CC<sub>50</sub> of 54.80 μM. Our finding of teriflunomide-mediated inhibition of SARS-CoV-2 infection at double-digit micromolar potency adds to a growing body of evidence for a broad-ranging antiviral effect of teriflunomide.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-07T13:22:05.013Z","creation":"2025-04-19T23:08:07.354Z"},"accession":"S-EPMC9682045","cross_references":{"pubmed":["36437966"],"doi":["10.1016/j.bbrep.2022.101395"]}}